[HTML] frontiersin.org

[HTML][HTML] What Is New in the Anti–Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?

S Reig, A Le Gouellec, S Bleves - Frontiers in Cellular and Infection …, 2022 - frontiersin.org
The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and
mortality worldwide. Carbapenem-resistant Pseudomonas aeruginosa (CRPA) are …
被引用次数：32 相关文章

What Is New in the Anti–Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?

S Reig, A Le Gouellec, S Bleves - Frontiers in Cellular and Infection …, 2022 - hal.science
The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and
mortality worldwide. Carbapenem-resistant Pseudomonas aeruginosa (CRPA) are …

What Is New in the Anti–Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?

S Reig, A Le Gouellec, S Bleves - Frontiers in Cellular and Infection …, 2022 - timc.fr
The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and
mortality worldwide. Carbapenem-resistant Pseudomonas aeruginosa (CRPA) are …

What Is New in the Anti-Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?

S Reig, A Le Gouellec, S Bleves - Frontiers in Cellular & …, 2022 - search.ebscohost.com
The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and
mortality worldwide. Carbapenem-resistant Pseudomonas aeruginosa (CRPA) are …
[HTML] nih.gov

[HTML][HTML] What Is New in the Anti–Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?

S Reig, A Le Gouellec, S Bleves - Frontiers in Cellular and Infection …, 2022 - ncbi.nlm.nih.gov
The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and
mortality worldwide. Carbapenem-resistant Pseudomonas aeruginosa (CRPA) are …

What Is New in the Anti–Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?

S Reig, A Le Gouellec, S Bleves - Frontiers in Cellular and Infection …, 2022 - amu.hal.science
The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and
mortality worldwide. Carbapenem-resistant Pseudomonas aeruginosa (CRPA) are …

What is new in the anti-Pseudomonas aeruginosa clinical development pipeline since the 2017 WHO alert?

S Reig, A le Gouellec, S Bleves - 2022 - cabidigitallibrary.org
The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and
mortality worldwide. Carbapenem-resistant Pseudomonas aeruginosa (CRPA) are …

What Is New in the Anti-Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?

S Reig, A Le Gouellec, S Bleves - Frontiers in Cellular and Infection …, 2022 - europepmc.org
The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and
mortality worldwide. Carbapenem-resistant Pseudomonas aeruginosa (CRPA) are …

What Is New in the Anti–Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?

S Reig, A Le Gouellec, S Bleves - 2022 - agris.fao.org
The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and
mortality worldwide. Carbapenem-resistant Pseudomonas aeruginosa (CRPA) are …

What Is New in the Anti–Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?

S Reig, A Le Gouellec, S Bleves - Frontiers in Cellular and Infection …, 2022 - cnrs.hal.science
The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and
mortality worldwide. Carbapenem-resistant Pseudomonas aeruginosa (CRPA) are …